Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $27.17.

Several research analysts recently issued reports on NTLA shares. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of Intellia Therapeutics in a research report on Monday, May 15th. Credit Suisse Group set a $24.00 target price on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Finally, Cann reaffirmed a “market perform” rating on shares of Intellia Therapeutics in a research report on Monday, July 17th.

Shares of Intellia Therapeutics (NTLA) opened at 22.20 on Friday. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $22.49. The company has a 50-day moving average price of $17.76 and a 200-day moving average price of $15.09. The company’s market cap is $801.69 million.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The firm’s quarterly revenue was up 40.5% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics will post ($1.78) earnings per share for the current year.

In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $167,000. California State Teachers Retirement System raised its position in shares of Intellia Therapeutics by 79.0% in the 2nd quarter. California State Teachers Retirement System now owns 25,143 shares of the company’s stock worth $402,000 after acquiring an additional 11,100 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Intellia Therapeutics by 451.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after acquiring an additional 10,825 shares in the last quarter. State Street Corp raised its position in shares of Intellia Therapeutics by 52.0% in the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after acquiring an additional 56,363 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Intellia Therapeutics by 19.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 48,566 shares of the company’s stock worth $777,000 after acquiring an additional 7,866 shares in the last quarter. 46.52% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/09/intellia-therapeutics-inc-ntla-receives-consensus-rating-of-buy-from-analysts.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.